Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors.
Jirovec E, Quixabeira DCA, Clubb JHA, Pakola SA, Kudling T, Arias V, Haybout L, Jalkanen K, Alanko T, Monberg T, Khammari A, Dreno B, Svane IM, Block MS, Adamo DA, Mäenpää J, Kistler C, Sorsa S, Hemminki O, Kanerva A, Santos JM, Cervera-Carrascon V, Hemminki A. Jirovec E, et al. J Exp Clin Cancer Res. 2024 Nov 6;43(1):297. doi: 10.1186/s13046-024-03219-0. J Exp Clin Cancer Res. 2024. PMID: 39506856 Free PMC article. Clinical Trial.
Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine.
Basnet S, Van der Heijden M, Quixabeira DCA, Jirovec E, Grönberg-Vähä-Koskela SAM, Clubb JHA, Kanerva A, Pakola S, Haybout L, Arias V, Hemminki O, Kudling T, Zafar S, Cervera-Carrascon V, Santos JM, Hemminki A. Basnet S, et al. Among authors: jirovec e. Mol Ther. 2024 Aug 7;32(8):2800. doi: 10.1016/j.ymthe.2024.07.009. Epub 2024 Jul 19. Mol Ther. 2024. PMID: 39029457 Free PMC article. No abstract available.
Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine.
Basnet S, Van der Heijden M, Quixabeira DCA, Jirovec E, Grönberg-Vähä-Koskela SAM, Clubb JHA, Kanerva A, Pakola S, Haybout L, Arias V, Hemminki O, Kudling T, Zafar S, Cervera-Carrascon V, Santos JM, Hemminki A. Basnet S, et al. Among authors: jirovec e. Mol Ther. 2024 Sep 4;32(9):3114-3127. doi: 10.1016/j.ymthe.2024.06.029. Epub 2024 Jun 22. Mol Ther. 2024. PMID: 38910324 Free PMC article.
Safety, Efficacy, and Biological Data of T-Cell-Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial.
Pakola SA, Peltola KJ, Clubb JHA, Jirovec E, Haybout L, Kudling TV, Alanko T, Korpisaari R, Juteau S, Jaakkola M, Sormunen J, Kemppainen J, Hemmes A, Pellinen T, van der Heijden M, Quixabeira DCA, Kistler C, Sorsa S, Havunen R, Santos JM, Cervera-Carrascon V, Hemminki A. Pakola SA, et al. Among authors: jirovec e. Clin Cancer Res. 2024 Sep 3;30(17):3715-3725. doi: 10.1158/1078-0432.CCR-23-3874. Clin Cancer Res. 2024. PMID: 38546220 Free PMC article. Clinical Trial.
Boosting cytotoxicity of adoptive allogeneic NK cell therapy with an oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer.
Quixabeira DCA, Pakola S, Jirovec E, Havunen R, Basnet S, Santos JM, Kudling TV, Clubb JHA, Haybout L, Arias V, Grönberg-Vähä-Koskela S, Cervera-Carrascon V, Kerkelä E, Pasanen A, Anttila M, Tapper J, Kanerva A, Hemminki A. Quixabeira DCA, et al. Among authors: jirovec e. Cancer Gene Ther. 2023 Dec;30(12):1679-1690. doi: 10.1038/s41417-023-00674-3. Epub 2023 Nov 10. Cancer Gene Ther. 2023. PMID: 37949944 Free PMC article.
Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine.
Quixabeira DCA, Jirovec E, Pakola S, Havunen R, Basnet S, Santos JM, Kudling TV, Clubb JHA, Haybout L, Arias V, Grönberg-Vähä-Koskela S, Cervera-Carrascon V, Pasanen A, Anttila M, Tapper J, Kanerva A, Hemminki A. Quixabeira DCA, et al. Among authors: jirovec e. Cancer Gene Ther. 2023 Nov;30(11):1543-1553. doi: 10.1038/s41417-023-00658-3. Epub 2023 Sep 4. Cancer Gene Ther. 2023. PMID: 37666898 Free PMC article.
An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage.
Pakola S, Quixabeira DCA, Kudling TV, Clubb JHA, Grönberg-Vähä-Koskela S, Basnet S, Jirovec E, Arias V, Haybout L, Heiniö C, Santos JM, Cervera-Carrascon V, Havunen R, Anttila M, Hemminki A. Pakola S, et al. Among authors: jirovec e. Front Immunol. 2023 Jul 5;14:1171083. doi: 10.3389/fimmu.2023.1171083. eCollection 2023. Front Immunol. 2023. PMID: 37475863 Free PMC article.
Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting.
Clubb JHA, Kudling TV, Girych M, Haybout L, Pakola S, Hamdan F, Cervera-Carrascon V, Hemmes A, Grönberg-Vähä-Koskela S, Santos JM, Quixabeira DCA, Basnet S, Heiniö C, Arias V, Jirovec E, Kaptan S, Havunen R, Sorsa S, Erikat A, Schwartz J, Anttila M, Aro K, Viitala T, Vattulainen I, Cerullo V, Kanerva A, Hemminki A. Clubb JHA, et al. Among authors: jirovec e. Front Immunol. 2023 Feb 3;14:1060540. doi: 10.3389/fimmu.2023.1060540. eCollection 2023. Front Immunol. 2023. PMID: 36817448 Free PMC article.
Engineering and combining oncolytic measles virus for cancer therapy.
Leber MF, Neault S, Jirovec E, Barkley R, Said A, Bell JC, Ungerechts G. Leber MF, et al. Among authors: jirovec e. Cytokine Growth Factor Rev. 2020 Dec;56:39-48. doi: 10.1016/j.cytogfr.2020.07.005. Epub 2020 Jul 3. Cytokine Growth Factor Rev. 2020. PMID: 32718830 Free PMC article. Review.